These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 10213505

  • 1. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
    Plonowski A, Schally AV, Nagy A, Sun B, Szepeshazi K.
    Cancer Res; 1999 Apr 15; 59(8):1947-53. PubMed ID: 10213505
    [Abstract] [Full Text] [Related]

  • 2. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
    Koppan M, Nagy A, Schally AV, Arencibia JM, Plonowski A, Halmos G.
    Cancer Res; 1998 Sep 15; 58(18):4132-7. PubMed ID: 9751625
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
    Plonowski A, Schally AV, Nagy A, Kiaris H, Hebert F, Halmos G.
    Cancer Res; 2000 Jun 01; 60(11):2996-3001. PubMed ID: 10850448
    [Abstract] [Full Text] [Related]

  • 4. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
    Plonowski A, Schally AV, Nagy A, Sun B, Halmos G.
    Int J Oncol; 2002 Feb 01; 20(2):397-402. PubMed ID: 11788908
    [Abstract] [Full Text] [Related]

  • 5. Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
    Kiaris H, Schally AV, Nagy A, Sun B, Szepeshazi K, Halmos G.
    Clin Cancer Res; 2000 Feb 01; 6(2):709-17. PubMed ID: 10690557
    [Abstract] [Full Text] [Related]

  • 6. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
    Chatzistamou L, Schally AV, Nagy A, Armatis P, Szepeshazi K, Halmos G.
    Clin Cancer Res; 2000 Oct 01; 6(10):4158-65. PubMed ID: 11051271
    [Abstract] [Full Text] [Related]

  • 7. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
    Szepeshazi K, Schally AV, Halmos G, Sun B, Hebert F, Csernus B, Nagy A.
    Clin Cancer Res; 2001 Sep 01; 7(9):2854-61. PubMed ID: 11555603
    [Abstract] [Full Text] [Related]

  • 8. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4505-13. PubMed ID: 14555524
    [Abstract] [Full Text] [Related]

  • 9. Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
    Szereday Z, Schally AV, Szepeshazi K, Bajo AM, Hebert F, Halmos G, Nagy A.
    Int J Oncol; 2003 May 01; 22(5):1141-6. PubMed ID: 12684683
    [Abstract] [Full Text] [Related]

  • 10. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J, Reile H, Halmos G, Groot K, Schally AV.
    Cancer Res; 1994 Jan 01; 54(1):169-74. PubMed ID: 7903203
    [Abstract] [Full Text] [Related]

  • 11. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
    Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD.
    Cancer Res; 1997 Apr 15; 57(8):1584-9. PubMed ID: 9108464
    [Abstract] [Full Text] [Related]

  • 12. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP.
    Clin Cancer Res; 2002 Aug 15; 8(8):2714-24. PubMed ID: 12171905
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
    Plonowski A, Schally AV, Letsch M, Krupa M, Hebert F, Busto R, Groot K, Varga JL.
    Prostate; 2002 Aug 01; 52(3):173-82. PubMed ID: 12111694
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines.
    Glinsky GV, Price JE, Glinsky VV, Mossine VV, Kiriakova G, Metcalf JB.
    Cancer Res; 1996 Dec 01; 56(23):5319-24. PubMed ID: 8968076
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A, Schally AV, Nagy A, Szepeshazi K, Kanashiro CA, Halmos G.
    Prostate; 2006 Feb 01; 66(2):200-10. PubMed ID: 16173040
    [Abstract] [Full Text] [Related]

  • 16. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
    Stangelberger A, Schally AV, Varga JL, Zarandi M, Szepeshazi K, Armatis P, Halmos G.
    Clin Cancer Res; 2005 Jan 01; 11(1):49-57. PubMed ID: 15671527
    [Abstract] [Full Text] [Related]

  • 17. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW, Schally AV, Radulovic S, Milovanovic S, Szepeshazi K, Isaacs JT.
    Cancer Res; 1992 May 01; 52(9):2538-44. PubMed ID: 1568223
    [Abstract] [Full Text] [Related]

  • 18. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
    Jackson JK, Gleave ME, Yago V, Beraldi E, Hunter WL, Burt HM.
    Cancer Res; 2000 Aug 01; 60(15):4146-51. PubMed ID: 10945622
    [Abstract] [Full Text] [Related]

  • 19. In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215.
    Plonowski A, Nagy A, Schally AV, Sun B, Groot K, Halmos G.
    Int J Cancer; 2000 Nov 15; 88(4):652-7. PubMed ID: 11058885
    [Abstract] [Full Text] [Related]

  • 20. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
    Engel JB, Keller G, Schally AV, Halmos G, Hammann B, Nagy A.
    Clin Cancer Res; 2005 Mar 15; 11(6):2408-15. PubMed ID: 15788692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.